HIV Lipodystrophy Meta-Analysis
5 RCTs confirming visceral fat reduction of -27.71 cm squared, trunk fat -1.18 kg, hepatic fat -4.28%, lean body mass +1.42 kg, without serious adverse events or glucose perturbation.
[1]A synthetic 44-amino-acid analog of human growth hormone-releasing hormone, modified with a trans-3-hexenoyl group at the N-terminus to resist proteolytic degradation. One of the very few peptides in regenerative medicine practice with full FDA approval.
At a glance
- Type
- Synthetic 44-amino-acid analog of human GHRH with a trans-3-hexenoyl N-terminus modification
- FDA approved
- Egrifta approved 2010 for excess abdominal fat in HIV lipodystrophy
- GHRH analog
- Strongest visceral and hepatic fat reduction evidence of any GHRH analog
- Proteolytic resistance
- N-terminus modification extends half-life and bioavailability in vivo
- Monitoring
- IGF-1 every 3 months per FDA labeling
- WADA
- Banned for competitive athletes
What the research supports
Tesamorelin's evidence base is anchored in FDA-approved use, a recent 2026 meta-analysis, and emerging MASLD applications.
Anti-Doping Detection
Established detection methodology for peptidic drugs including Tesamorelin in doping control blood samples, confirming pharmacological activity and systemic presence.
[2]GHRH Axis Pharmacology Review
Reviews GHRH agonist and antagonist therapeutics including the Tesamorelin mechanism class, contextualizing its role in the broader GH axis pharmacology landscape.
[3]Selective Visceral Fat Reduction
Defining clinical feature: reduces visceral adipose tissue more than subcutaneous fat, differentiating Tesamorelin from most GH-elevating strategies currently in use.
Summary of key findings
FDA-Approved Peptide
Egrifta approval (2010) gives Tesamorelin one of the strongest evidence and safety bases in the entire peptide space.
Visceral and Hepatic Fat Selectivity
Mean visceral fat reduction approximately 28 cm squared and hepatic fat reduction 4.28% confirmed in the 2026 meta-analysis.
No Glucose Perturbation
Differentiates Tesamorelin from MK-677 for metabolic syndrome and prediabetic patients requiring GH axis support.
NAFLD and MASLD Positioning
The hepatic fat reduction effect makes Tesamorelin one of the most actionable off-label peptides for fatty liver disease management.
Dosing guide
From published protocols. Licensed provider supervision assumed throughout.
- FDA Approved Dose (Egrifta)
- 2 mg subcutaneous once daily, evening preferred. Continuous per FDA labeling.
- Functional Medicine Dosing
- 1 to 2 mg SC daily. Some protocols start at 1 mg in sensitive patients to assess tolerability.
- Cycling Protocol
- Some functional protocols cycle 3 to 6 months on with 1 to 2 month breaks from continuous use.
- Monitoring
- IGF-1 every 3 months per FDA labeling. Target mid-to-upper reference range throughout therapy.
Vial reference
Units are for a U-100 insulin syringe (100 units = 1 mL), computed from the vial concentration.
| Vial | Dose range | Units per dose | Frequency | Notes |
|---|---|---|---|---|
| Tesamorelin 8 mg / 1 mL | 1 to 2 mg | 12.5 to 25 units | 5 days on, 2 off | 0.08 mg per unit. PM empty stomach 60 to 90 minutes after last meal. Before bedtime. |
| Tesamorelin 10 mg / 1 mL | 1 to 2 mg | 10 to 20 units | 5 days on, 2 off | 0.1 mg per unit. PM empty stomach 60 to 90 minutes after last meal. 8 months on, 1 month off. |
A starting dose of 0.5 mg is recommended before titration to 1 mg or more.
Reference ranges as published in the source protocol document, not a prescription. To work out the draw for a specific vial and dose, use the Peptide Calculator.
Bottom line
Tesamorelin is one of the very few FDA-approved peptides on the regenerative medicine list. The defining clinical feature is selective visceral fat reduction. The 2026 meta-analysis confirms substantial VAT reduction without compromise of lean body mass, differentiating Tesamorelin from most GH-elevating strategies. Position for patients with documented visceral adiposity, metabolic syndrome, or NAFLD/MASLD. Glucose effects are minimal compared to other GH-elevating strategies, making Tesamorelin preferred over MK-677 for metabolic syndrome and prediabetic patients. Monitor IGF-1 every 3 months per FDA labeling. WADA banned for competitive athletes.
Visceral Fat Reduction
Selective VAT reduction confirmed in 2026 meta-analysis without lean mass compromise
Hepatic Fat Reduction
4.28% hepatic fat reduction supports NAFLD/MASLD clinical applications
FDA Approved Class
Strongest regulatory standing among regenerative GHRH analogs available today
References
Citations sourced from PubMed and verified against the PubMed record.
- 1Badran et al., 2026 Tesamorelin in HIV lipodystrophy meta-analysis
- 2Thomas et al., 2022 Detection of peptidic drugs including Tesamorelin in doping control blood samples
- 3Costoya et al., 2024 GHRH antagonism for AML and axis pharmacology review
- 4Falutz et al., 2007 Tesamorelin (Egrifta) HIV lipodystrophy FDA approval pivotal trial
Regulatory status, cautions and contraindications
Active Malignancy
Contraindicated per FDA labeling. Do not use in patients with active or suspected malignancy.
Pregnancy and Lactation
Contraindicated. Safety has not been established in pregnant or breastfeeding individuals.
Active Retinopathy
Use with caution. Monitor closely in patients with pre-existing retinal conditions.
WADA Banned
Tesamorelin is banned for competitive athletes under the World Anti-Doping Agency prohibited list.
Legal disclaimer
These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
This peptide overview is for informational purposes only and does not constitute medical advice. The information provided here is not intended to diagnose, treat, cure, or prevent any disease. Peptide therapies should only be used under the guidance of a licensed healthcare provider, who can assess individual health needs and determine appropriate dosing and administration.
Always consult your healthcare provider before starting any new treatment, as misuse or improper dosing may lead to adverse effects. The efficacy and safety of peptide therapies have not been fully established in all cases, and ongoing medical supervision is essential.